Summary
Acknowledging fungal infections as a global problem, all three initiatives explicitly reach out beyond European borders.
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| INTRODUCTION
Based on population and disease demographics it is estimated that globally over 1 billion people are afflicted with a fungal infection and 25 million are at high risk of dying or losing their eyesight. Human and Animal Mycology (ISHAM) which has a focus on fundamental mycology research. 9 Where clinical and fundamental research meet, both organisations establish common working groups, eg on rare invasive fungal infections or on azole resistant aspergillosis.
In an effort to guide clinicians, mycologists and patients, and to emphasise excellence in clinical care and research, ECMM launched three distinct initiatives since 2011: Guideline development programme, ECMM Academy programme, and ECMM Excellence Center programme. A key part of the ECMM ECs work is the interplay of experts from all areas needed to ensure leadership commitment. This is to ensure that every patient gets the correct diagnosis, optimal drug choice, dose, duration and route of administration while minimising resistance development and toxicity. Hence, an ECMM EC with Gold designation may require the interplay of 6 to >10 local departments or disciplines with key support in patient management. As an example, the treatment of a haematological malignancy patient with disseminated lung and liver mucormycosis requires experts in adult or paediatric haematology, infectious diseases, microbiology, radiology, pulmonology, gastroenterology, surgery (visceral, thoracic), pathology, and intensive care medicine (Table 3 ).
| THREE STEPS TOWARDS EXCELLENT DIAGNOSTICS AND EXCELLENT TREATMENT

| European guideline initiative
| ECMM excellence centres
The ECMM audit plan comprises detailed information of all type of procedures implemented in the institution. Regarding the diagnostic Manchester has been designated Diamond status; others will follow.
| CONCLUSIONS
In an effort to guide clinicians, mycologists and patients, and to empha- 
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